(Q35976416)

11 August 2017

1 reference

title

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions (English)

1 reference

cost-effectiveness analysis

11 August 2017

1 reference

1 reference

1 reference

Kathryn A Phillips

1

1 reference

PubMed ID

15584880

11 August 2017

Stephanie L Van Bebber

series ordinal

2

1 reference

11 August 2017

1 December 2004

1 reference

11 August 2017

1 reference

11 August 2017

5

1 reference

11 August 2017

8

1 reference

11 August 2017

1139-1149

1 reference

Drug methylation in cancer therapy: lessons from the TPMT polymorphism

11 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Searching literature databases for health care economic evaluations: how systematic can we afford to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Assessing the cost-effectiveness of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Cancer: understanding the target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

Medicare coverage for technological innovations--time for new criteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.8.1139

10.1517/14622416.5.8.1139

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15584880